Teladoc (TDOC - Free Report) closed at $5.73 in the latest trading session, marking a +1.06% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.41%. Meanwhile, the Dow experienced a drop of 0.07%, and the technology-dominated Nasdaq saw an increase of 1.11%.
Shares of the telehealth services provider witnessed a loss of 10% over the previous month, trailing the performance of the Medical sector with its gain of 1.97%, and the S&P 500's gain of 1.46%.
Analysts and investors alike will be keeping a close eye on the performance of Teladoc in its upcoming earnings disclosure. The company's earnings report is set to go public on October 28, 2026. The company's earnings per share (EPS) are projected to be -$0.23, reflecting a 9.52% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $585.55 million, down 6.53% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.92 per share and a revenue of $2.4 billion, indicating changes of +19.3% and -5.03%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Teladoc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Teladoc holds a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 155, this industry ranks in the bottom 37% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Counterpoint Mutual Funds LLC increased its position in shares of Teladoc Health, Inc. (NYSE:TDOC – Free Report) by 1,017.4% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,650,165 shares of the health services provider’s stock after purchasing an additional 1,502,488 shares during the quarter. Teladoc Health makes up approximately 0.8% of Counterpoint Mutual Funds LLC’s holdings, making the stock its 26th biggest holding. Counterpoint Mutual Funds LLC owned approximately 0.91% of Teladoc Health worth $9,571,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in TDOC. Vontobel Holding Ltd. grew its stake in Teladoc Health by 98.4% during the third quarter. Vontobel Holding Ltd. now owns 93,210 shares of the health services provider’s stock worth $541,000 after buying an additional 46,227 shares during the last quarter. ABS Direct Equity Fund LLC bought a new position in shares of Teladoc Health in the second quarter valued at approximately $1,513,000. WINTON GROUP Ltd raised its stake in shares of Teladoc Health by 402.4% in the second quarter. WINTON GROUP Ltd now owns 227,100 shares of the health services provider’s stock valued at $1,926,000 after acquiring an additional 181,900 shares during the last quarter. Nykredit A S acquired a new position in shares of Teladoc Health in the 2nd quarter worth approximately $27,000. Finally, HighTower Advisors LLC boosted its holdings in shares of Teladoc Health by 20.8% in the 2nd quarter. HighTower Advisors LLC now owns 16,808 shares of the health services provider’s stock worth $143,000 after acquiring an additional 2,893 shares in the last quarter. 76.82% of the stock is owned by institutional investors.
Insider Transactions at Teladoc Health In related news, CEO Charles III sold 17,805 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $6.10, for a total value of $108,610.50. Following the sale, the chief executive officer directly owned 465,535 shares in the company, valued at $2,839,763.50. This trade represents a 3.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.70% of the company’s stock.
Teladoc Health Price Performance TDOC stock opened at $5.68 on Friday. The company has a 50 day moving average price of $6.22 and a 200 day moving average price of $6.87. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The stock has a market capitalization of $1.03 billion, a PE ratio of -5.74 and a beta of 2.14. Teladoc Health (NYSE:TDOC – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. The firm had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative return on equity of 12.15% and a negative net margin of 7.13%. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period last year, the company earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, equities analysts expect that Teladoc Health, Inc. will post -0.92 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on TDOC shares. Bank of America increased their price target on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Canaccord Genuity Group cut their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Citigroup reduced their price objective on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research note on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.54.
Get Our Latest Stock Report on Teladoc Health
Teladoc Health Profile (Free Report)
Teladoc Health, Inc (NYSE: TDOC) provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.
The company’s offerings include Teladoc’s telehealth services, BetterHelp’s online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.
Further Reading Five stocks we like better than Teladoc Health Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2026 results on Wednesday, October 28, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day.
Conference Call Details
The conference call can be accessed by dialing 833-461-5787 for U.S. participants and using the meeting ID # 404 870 451.
For international participants, please visit the following link for global dial-in numbers, using the same meeting ID # 404 870 451: https://help.events.q4inc.com/eahc/international-dial-in-numbers. A live audio webcast will also be available online at https://ir.teladoc.com/news-and-events/events-and-presentations/.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
In the latest trading session, Teladoc (TDOC - Free Report) closed at $6.00, marking a +1.35% move from the previous day. This change outpaced the S&P 500's 0.02% loss on the day. Meanwhile, the Dow experienced a drop of 0.35%, and the technology-dominated Nasdaq saw a decrease of 0.15%.
The telehealth services provider's shares have seen a decrease of 8.92% over the last month, not keeping up with the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. The company is expected to report EPS of -$0.23, down 9.52% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $585.55 million, showing a 6.53% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.92 per share and revenue of $2.4 billion, which would represent changes of +19.3% and -5.03%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Teladoc presently features a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 101, finds itself in the top 42% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Key Takeaways Teladoc adds SoloVitals and SoloScribe to strengthen its connected care platform for hospitals.SoloVitals uses smartphone cameras to estimate heart and respiratory rates during virtual assessments.SoloScribe creates clinical notes and transfers summaries to EHRs, reducing repetitive documentation work. Teladoc Health, Inc. (TDOC - Free Report) is expanding its Solo connected care platform with two new AI-powered tools designed to make virtual consultations more useful for clinicians and less cumbersome for hospitals. SoloVitals and SoloScribe address different bottlenecks in remote care: obtaining timely patient information and documenting visits without pulling attention away from patients.
SoloVitals uses the camera on a smartphone or tablet to estimate heart and respiratory rates by detecting subtle changes in facial skin color. The contactless approach could give clinicians another source of information during virtual assessments. SoloScribe, meanwhile, generates structured clinical notes and transfers summaries into electronic health records (EHR), potentially reducing repetitive documentation work.
By bringing these capabilities together within Solo, Teladoc is making its platform more useful for hospitals seeking to simplify their technology systems. Already installed in more than 15,000 care locations worldwide, Solo integrates with EHR systems such as Epic and Oracle Health. SoloScribe is now generally available, while SoloVitals is currently available to select customers through a private preview. Teladoc expects SoloVitals to reach full general release in December 2026.
The expansion could also strengthen Teladoc's position in the increasingly competitive virtual healthcare market. By combining clinical documentation and remote patient assessment within one platform, Teladoc could help hospitals reduce administrative workloads, improve clinical workflows and deliver more efficient patient care.
The introduction of these tools adds another dimension to Teladoc's efforts to strengthen its enterprise healthcare business. Growing demand for AI-enabled healthcare solutions provides an opportunity to expand its reach, while its established presence among hospitals and health systems offers a foundation for adoption. Wider adoption of these capabilities could strengthen customer retention, increase platform utilization and support sustainable revenue growth, contributing to Teladoc's long-term growth prospects.
TDOC’s Price PerformanceOver the past six months, TDOC’s shares have gained 5.9% compared with the industry’s growth of 11.6%.
Image Source: Zacks Investment Research
TDOC’s Zacks Rank & Key PicksTDOC currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Medical space are Concentra Group Holdings Parent, Inc. (CON - Free Report) , Phibro Animal Health Corporation (PAHC - Free Report) and GeneDx Holdings Corp. (WGS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Concentra Group’s current-year earnings of $1.65 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. CON beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.3%. The consensus estimate for current-year revenues is pegged at $2.4 billion, suggesting 8.7% year-over-year growth.
The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.50 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. PAHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 18.4%. The consensus estimate for current-year revenues is pegged at $1.6 billion, suggesting 3.8% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. WGS beat earnings estimates in three of the trailing four quarters and missed once. The consensus estimate for current-year revenues is pegged at $478 million, suggesting 11.8% year-over-year growth.
In the latest trading session, Teladoc (TDOC - Free Report) closed at $5.56, marking a -3.64% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.22%. Elsewhere, the Dow saw a downswing of 0.66%, while the tech-heavy Nasdaq depreciated by 0.22%.
Shares of the telehealth services provider have depreciated by 7.83% over the course of the past month, underperforming the Medical sector's loss of 4.73%, and the S&P 500's gain of 1.4%.
The upcoming earnings release of Teladoc will be of great interest to investors. On that day, Teladoc is projected to report earnings of -$0.23 per share, which would represent a year-over-year decline of 9.52%. Alongside, our most recent consensus estimate is anticipating revenue of $585.55 million, indicating a 6.53% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.92 per share and a revenue of $2.4 billion, demonstrating changes of +19.3% and -5.03%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Teladoc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Teladoc presently features a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 105, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
New SoloVitals and SoloScribe capabilities bring contactless vitals and ambient documentation directly into clinical workflows | Source: Teladoc Health, Inc.
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced two new AI-powered capabilities within Solo, its enterprise smart care platform for hospitals and health systems. SoloVitals and SoloScribe are designed to help health systems bring timely patient insights into the care environment, while reducing technology fragmentation and helping care teams stay focused on patient care.
“Health systems are under intense pressure to do more, yet they are spending more time navigating a growing number of platforms, tools and vendors, each requiring different technology and processes. Teladoc Health is extending care teams with embedded, clinically-validated AI, without the added complexity,” said Joby McKenzie, General Manager, North American Health Systems at Teladoc Health.
SoloVitals is an AI-powered contactless vital sign measurement solution that can capture heart rate and respiration rate without physically touching a patient. Using a patient’s existing camera-equipped device, such as a smart phone or tablet, SoloVitals analyzes subtle facial skin color changes through remote photoplethysmography (rPPG) technology to generate measurements. This capture provides clinicians with clinically-validated vital sign measurement during remote consultations to support better care decisions.
SoloScribe is an ambient AI documentation scribe that creates structured clinical notes in Solo, helping clinicians remain focused on the patient while documentation stays embedded in the virtual care workflow. SoloScribe supports both direct-to-patient and telemedicine device-based visits and creates a templated summary that is transferred into the EHR. This helps hospitals scale AI-assisted documentation across eligible clinicians, programs and workflows through one integrated Solo experience.
Both capabilities are embedded within Teladoc Health’s Solo platform, rather than requiring multiple disconnected point solutions. This creates a more scalable approach to AI-enabled care delivery that helps extend clinical teams, surface timely patient insights, and simplify technology management.
“When we embed practical AI directly into clinical workflows through one connected platform, we are helping to provide faster access to patient information, reduce administrative burdens, and enable hospitals to scale innovation without adding new infrastructure. This allows clinicians to remain focused on their patients and not on the technology or processes surrounding a care interaction,” said Danny Sanchez, Vice President of Technology and Innovation at Teladoc Health.
Teladoc Health’s Solo technology is installed in more than 15,000 care locations globally and offers deep integrations with EHR platforms such as Epic and Oracle Health using HL7 and FHIR standards.
SoloScribe is now generally available, and SoloVitals is available to select customers in private preview, with full general release expected in December 2026. For more information about Teladoc Health’s enterprise solutions for hospitals and health systems, click here.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Teladoc Health (NYSE:TDOC – Get Free Report) and National Research (NASDAQ:NRC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Earnings and Valuation This table compares Teladoc Health and National Research”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teladoc Health $2.53 billion 0.40 -$200.32 million ($0.99) -5.59 National Research $137.39 million 3.37 $11.60 million $0.25 81.40 National Research has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks. Volatility and Risk Teladoc Health has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, National Research has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.
Analyst Ratings This is a breakdown of current ratings for Teladoc Health and National Research, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teladoc Health 1 10 5 0 2.25 National Research 0 1 1 0 2.50 Teladoc Health currently has a consensus price target of $7.54, indicating a potential upside of 36.12%. National Research has a consensus price target of $26.00, indicating a potential upside of 27.76%. Given Teladoc Health’s higher probable upside, analysts clearly believe Teladoc Health is more favorable than National Research.
Institutional and Insider Ownership 76.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 47.3% of National Research shares are owned by institutional investors. 0.7% of Teladoc Health shares are owned by insiders. Comparatively, 9.2% of National Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability This table compares Teladoc Health and National Research’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Teladoc Health -7.13% -12.15% -5.83% National Research 4.18% 164.26% 14.67% Summary National Research beats Teladoc Health on 9 of the 14 factors compared between the two stocks.
About Teladoc Health (Get Free Report)
Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.
(Get Free Report)
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
Teladoc (TDOC - Free Report) closed the most recent trading day at $5.75, moving -2.38% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq depreciated by 0.09%.
The telehealth services provider's shares have seen a decrease of 7.1% over the last month, not keeping up with the Medical sector's loss of 0.67% and the S&P 500's loss of 0.24%.
The investment community will be paying close attention to the earnings performance of Teladoc in its upcoming release. On that day, Teladoc is projected to report earnings of -$0.23 per share, which would represent a year-over-year decline of 9.52%. Our most recent consensus estimate is calling for quarterly revenue of $585.55 million, down 6.53% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.92 per share and revenue of $2.4 billion, indicating changes of +19.3% and -5.03%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Teladoc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.62% decrease. Teladoc presently features a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 99, this industry ranks in the top 41% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Corient Private Wealth LP trimmed its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC – Free Report) by 62.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 101,556 shares of the health services provider’s stock after selling 171,447 shares during the period. Corient Private Wealth LP owned approximately 0.06% of Teladoc Health worth $861,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock valued at $44,066,000 after buying an additional 107,400 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Teladoc Health during the second quarter valued at $26,864,000. Pale Fire Capital SE boosted its holdings in Teladoc Health by 74.8% in the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock worth $18,522,000 after acquiring an additional 1,454,288 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after acquiring an additional 1,471,631 shares in the last quarter. Finally, Freestone Grove Partners LP purchased a new stake in shares of Teladoc Health in the second quarter worth $7,338,000. 76.82% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth TDOC has been the topic of a number of research reports. Citigroup dropped their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a report on Monday, August 3rd. Bank of America upped their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Finally, Canaccord Genuity Group dropped their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.54.
Get Our Latest Analysis on TDOC Teladoc Health Stock Performance TDOC opened at $6.10 on Monday. Teladoc Health, Inc. has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The firm’s fifty day moving average is $6.90 and its 200 day moving average is $6.85. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -6.16 and a beta of 2.12.
Teladoc Health (NYSE:TDOC – Get Free Report) last issued its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The company had revenue of $606.93 million during the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. Teladoc Health’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, equities research analysts predict that Teladoc Health, Inc. will post -0.92 earnings per share for the current year.
Insider Buying and Selling In related news, CEO Charles III sold 17,805 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer directly owned 465,535 shares of the company’s stock, valued at approximately $2,839,763.50. The trade was a 3.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company’s stock.
Teladoc Health Company Profile (Free Report)
Teladoc Health, Inc is a virtual healthcare company that provides telehealth services and technology to individuals, employers, health plans, health systems and other organizations. Its platform enables patients to connect with healthcare professionals remotely through phone, video and digital tools, supporting access to medical care across a range of specialties.
The company’s offerings include general medical consultations, mental health services through BetterHelp, expert medical opinions, chronic condition management and digital health programs.
Featured Articles Five stocks we like better than Teladoc Health Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind 3 More AI Infrastructure Plays Beyond the Big Names CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026 Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026
In the latest trading session, Teladoc (TDOC - Free Report) closed at $6.13, marking a -3.46% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.68%, and the technology-centric Nasdaq decreased by 1.13%.
Prior to today's trading, shares of the telehealth services provider had gained 2.58% outpaced the Medical sector's loss of 3.03% and the S&P 500's gain of 1.26%.
Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$0.23, reflecting a 9.52% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $585.55 million, indicating a 6.53% decrease compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.92 per share and revenue of $2.4 billion. These totals would mark changes of +19.3% and -5.03%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Teladoc. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.78% lower. At present, Teladoc boasts a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 88, placing it within the top 36% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Teladoc (TDOC - Free Report) ended the recent trading session at $6.28, demonstrating a -2.33% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.14%. At the same time, the Dow added 0.61%, and the tech-heavy Nasdaq gained 1.69%.
Prior to today's trading, shares of the telehealth services provider had lost 3.45% lagged the Medical sector's loss of 0.26% and the S&P 500's loss of 2.85%.
Market participants will be closely following the financial results of Teladoc in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.23, reflecting a 9.52% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $585.55 million, down 6.53% from the year-ago period.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$0.92 per share and revenue of $2.4 billion. These results would represent year-over-year changes of +19.3% and -5.03%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Teladoc. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.28% lower. Teladoc is holding a Zacks Rank of #3 (Hold) right now.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 93, placing it within the top 38% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
SummaryTeladoc Health trades near multi-year lows, with the market pricing in deep distress despite meaningful free cash flow and manageable debt.BetterHelp's rapid decline drags on TDOC, but Integrated Care's improving margins and growing revenue per member offer stabilization.TDOC's valuation is extremely depressed, trading at just 7–8x expected free cash flow, with fair value estimates suggesting significant upside even under conservative scenarios.If Integrated Care remains stable and BetterHelp's insurance transition succeeds, TDOC could justify a price range of $9–$21, far above current levels.Editor's note: Seeking Alpha is proud to welcome Abd-Allah Youssef as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.
1 Follower
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Teladoc (TDOC - Free Report) ended the recent trading session at $6.16, demonstrating a +1.15% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.86%. Meanwhile, the Dow gained 0.98%, and the Nasdaq, a tech-heavy index, added 0.96%.
Prior to today's trading, shares of the telehealth services provider had lost 12.5% lagged the Medical sector's loss of 2.34% and the S&P 500's loss of 1.96%.
The investment community will be paying close attention to the earnings performance of Teladoc in its upcoming release. The company's upcoming EPS is projected at -$0.22, signifying a 4.76% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $585.55 million, down 6.53% from the prior-year quarter.
TDOC's full-year Zacks Consensus Estimates are calling for earnings of -$0.9 per share and revenue of $2.4 billion. These results would represent year-over-year changes of +21.05% and -5.03%, respectively.
It is also important to note the recent changes to analyst estimates for Teladoc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.83% fall in the Zacks Consensus EPS estimate. Teladoc is currently sporting a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Key Takeaways Integrated Care delivered $394.3 million in revenues and $65.2 million in adjusted EBITDA in Q2 2026.BetterHelp's shift to insurance contrasts with Integrated Care's enterprise contracts and chronic care growth.Teladoc One will unite primary and chronic care services, strengthening Integrated Care's earnings role. Teladoc Health, Inc.’s (TDOC - Free Report) Integrated Care is increasingly becoming the more dependable part of the business. Its growth is modest, but the segment is becoming more profitable as chronic care gains traction. That matters because Teladoc’s investment case is no longer solely about fixing BetterHelp. Increasingly, it hinges on whether Integrated Care can contribute a larger share of the company’s earnings as Teladoc builds a broader healthcare platform.
Integrated Care is now driving most of Teladoc’s earnings. The segment generated $394.3 million in revenue and $65.2 million in adjusted EBITDA in the second quarter, compared with just $0.5 million of adjusted EBITDA from BetterHelp. With consolidated adjusted EBITDA at $65.7 million, Integrated Care is clearly the primary driver of profitability.
The two businesses face very different economics. BetterHelp is dealing with the shift from cash-pay to insurance, while provider availability remains a constraint. Integrated Care runs on enterprise contracts and has more room to grow revenues through chronic care bundles and services like Teladoc One. That gives the segment a clearer path to expand without relying on a major increase in membership.
Teladoc One, set for broad launch in January 2027, will integrate primary care, chronic care and other services around the same patient. If adoption builds, Integrated Care could become Teladoc’s main earnings driver, giving the company a steadier path to profit growth even if overall membership growth remains modest.
How Are Competitors Faring?Some of Teladoc’s key peers across digital health are Hims & Hers Health, Inc. (HIMS - Free Report) and Omada Health, Inc. (OMDA - Free Report) .
Hims & Hers Health operates a consumer-focused digital healthcare platform spanning areas such as weight management, sexual health, dermatology and mental health. Its direct-to-consumer model has helped HIMS scale quickly, making customer growth, engagement and marketing efficiency important drivers of its performance.
Omada Health focuses on virtual care for chronic conditions, including diabetes, hypertension, weight management and musculoskeletal conditions. It provides recurring access to a growing member base, while its multi-condition platform allows OMDA to expand relationships across different areas of care.
Teladoc Health’s Price Performance, Valuation & EstimatesShares of TDOC have gained 18.5% over the past six months compared with the industry’s 8.1% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, TDOC trades at a forward price-to-sales ratio of 0.47X, down from the industry average of 0.53X. TDOC carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TDOC’s 2026 loss is pegged at 89 cents per share,implying a 21.9% increase from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to a new employee.
Effective September 1, 2026, in connection with commencing employment as Chief Financial Officer, Michael Grasher was granted an award of restricted stock units covering 239,616 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and awards of performance stock units covering a target of 239,616 shares of Common Stock (for which up to 479,232 shares may be earned). The restricted stock units vest, based on continued service to Teladoc Health as to one-half of the underlying shares on the first anniversary of the grant date, with the remainder vesting in six substantially equal quarterly installments beginning on the 15-month anniversary of the grant date. The performance stock units provide a target number of shares of Common Stock that would be earned based on (i) Teladoc Health’s adjusted EBITDA for 2026 (“EBITDA PSUs”) and (ii) Teladoc Health’s actual compound annual revenue growth rate during 2026-2028 (“Revenue CAGR PSUs”). One-half of any earned EBITDA PSUs would vest on the first anniversary of the grant date and the remaining one-half would vest in six substantially equal quarterly installments beginning on the 15-month anniversary of the grant date. Any earned Revenue CAGR PSUs would vest on March 1, 2029.
The awards were approved by the Compensation Committee of the Board of Directors of Teladoc Health and were granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as employment inducement awards pursuant to New York Stock Exchange Rule 303A.08.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at www.teladochealth.com.
Key Takeaways Teladoc Health is expanding through chronic care, international growth and its upcoming Teladoc One platform.BetterHelp revenues fell 11.6%, while its adjusted EBITDA margin dropped to 0.2% in Q2 2026.TDOC remains unprofitable and faces intense virtual-care competition that could pressure growth and pricing. Teladoc Health, Inc. (TDOC - Free Report) is well-positioned for growth, supported by broad clinical capabilities, connected-care innovation, strategic acquisitions and an expanding international presence. Over the past six months, TDOC stock has gained 22.7% compared with the industry’s 5.9% growth.
With a market capitalization of approximately $1.1 billion, TDOC operates through two main segments — Integrated Care and BetterHelp. From a valuation standpoint, the stock appears to be trading at a discount. The company has a forward Price-to-Sales ratio of 0.47X, which is below the industry average of 0.53X.
Courtesy of solid prospects, TDOC currently carries a Zacks Rank #3 (Hold) and a Value Score of B.
Where Do Estimates for TDOC Stand?The Zacks Consensus Estimate for Teladoc Health’s 2026 loss is pegged at 89 cents per share, suggesting a 21.9% year-over-year increase. In the past 30 days, it has witnessed three upward estimate revisions against one in the opposite direction. The consensus estimate for revenues is pegged at $2.4 billion for 2026.
TDOC beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 11.4%.
TDOC’s Growth DriversTeladoc Health’s growth prospects are increasingly tied to deeper penetration of its Integrated Care platform, particularly chronic care. Chronic Care Program enrollment reached 1.27 million at the end of June 2026, up 14% year over year, helped by greater adoption of multi-condition bundles. In the second quarter of 2026, Integrated Care revenues increased 0.7% year over year to $394.3 million, with hybrid care revenues rising 30%.
International expansion and broader distribution channels provide another avenue for growth. International revenues increased 7% year over year to $119.6 million in the second quarter of 2026. The company expects international revenues to grow in the high-single digit on an organic constant-currency basis in 2026. The Telecare acquisition also contributed to Integrated Care’s revenue growth in the second quarter, supporting Teladoc Health’s international expansion strategy. Additionally, partnerships with platforms such as Walmart are extending Teladoc Health’s reach beyond traditional employer and health-plan channels, giving consumers easier access to virtual urgent care, dermatology and nutrition services.
A major part of Teladoc Health’s next phase is Teladoc One, a more unified care model that combines multidisciplinary care teams, connected health data and always-on AI support. The platform is designed to coordinate care across chronic conditions, mental health, primary care and other needs rather than treating each condition separately. Programs are scheduled to begin with select clients in September 2026, followed by broader availability in January 2027.
Meanwhile, BetterHelp is undergoing a strategic shift toward insurance-based, in-network services, which could create a more durable growth model over time. The company has contracted for more than 150 million in-network lives and credentialed more than 8,000 mental-health professionals. TDOC is also investing in provider recruitment, network capacity, platform efficiency and targeted marketing to support further growth in its insurance-based business.
Risks for TDOC StockThere are some factors, however, that investors should keep a careful eye on.
BetterHelp remains a key concern for Teladoc Health as weakness in the cash-pay mental health business continues to weigh on results. BetterHelp revenues declined 11.6% year over year to $212.6 million in the second quarter of 2026, while its adjusted EBITDA margin fell to just 0.2%.
Teladoc Health faces intense competition in the virtual care market, which could pressure pricing and growth. The company also remains unprofitable, reporting an accumulated deficit of $16.5 billion as of June 30, 2026, largely due to substantial investments in growth initiatives and technology.
Stocks to ConsiderSome better-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Globus Medical, Inc. (GMED - Free Report) and Centene Corporation (CNC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.82 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.3 billion, suggesting 18.2% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.99 per share has witnessed one upward revision in the past seven days, against no movement in the opposite direction. GMED beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed two upward revisions in the past 30 days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.
Connor Clark & Lunn Investment Management Ltd. bought a new position in Teladoc Health, Inc. (NYSE:TDOC – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 87,511 shares of the health services provider’s stock, valued at approximately $742,000.
Several other hedge funds have also modified their holdings of TDOC. Allworth Financial LP bought a new stake in shares of Teladoc Health in the 2nd quarter valued at about $25,000. EverSource Wealth Advisors LLC raised its stake in shares of Teladoc Health by 694.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock worth $31,000 after acquiring an additional 4,945 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after acquiring an additional 2,810 shares in the last quarter. IFP Advisors Inc lifted its position in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in Teladoc Health during the fourth quarter valued at approximately $45,000. 76.82% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth Several research firms have issued reports on TDOC. Canaccord Genuity Group cut their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Bank of America increased their price objective on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Citigroup lowered their price objective on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research report on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teladoc Health in a research note on Wednesday, August 19th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.54.
Check Out Our Latest Research Report on TDOC Teladoc Health Stock Down 2.3% Shares of Teladoc Health stock opened at $6.35 on Tuesday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -6.41 and a beta of 2.12. The company has a 50 day moving average price of $7.91 and a 200 day moving average price of $6.66. Teladoc Health, Inc. has a 52 week low of $4.40 and a 52 week high of $9.89.
Teladoc Health (NYSE:TDOC – Get Free Report) last released its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. The company had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. Teladoc Health’s revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, research analysts anticipate that Teladoc Health, Inc. will post -0.89 earnings per share for the current fiscal year.
About Teladoc Health (Free Report)
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
Further Reading Five stocks we like better than Teladoc Health Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
Appointment brings seasoned financial leadership as Teladoc Health advances its strategy aimed at delivering disciplined, sustainable growth
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Michael Grasher as Chief Financial Officer, effective immediately.
Mr. Grasher is an accomplished financial executive with more than three decades of experience across the insurance and financial services sectors, including more than 12 years in CFO roles at public and privately held companies.
He most recently served as CFO of IFG Companies, a privately held property-casualty insurance organization, where he was responsible for financial reporting, planning and analysis, and treasury management. Previously, Mr. Grasher served as CFO and Executive Vice President of Fortegra, a global specialty insurer, overseeing financial governance and accounting across U.S. and European operations, among other duties. Prior to Fortegra, he served as CFO and Executive Vice President of AMERISAFE, a publicly traded specialty provider of workers’ compensation insurance, where he led financial reporting, capital management and investor relations. Before moving into corporate finance leadership, he spent more than a decade in equity research as both a buy- and sell-side analyst, including as a Managing Director at Piper Jaffray, now Piper Sandler.
“Mike is an experienced financial leader with a proven record of financial stewardship, driving operational discipline and strategic execution,” said Chuck Divita, Chief Executive Officer of Teladoc Health. “Mike’s combination of public company experience, financial leadership and operating discipline will be particularly valuable as we continue to strengthen the business, execute our strategic priorities and deliver long-term value for our stakeholders.”
Throughout his career, Mr. Grasher has supported sustained growth, profitability and corporate strategy across the companies he has served and brings experience leading enterprise-wide efficiency initiatives and shaping long-term strategy.
“Teladoc Health has built a strong foundation with unmatched scale, deep clinical expertise and a global footprint,” said Grasher. “I’m excited to work with Chuck and the leadership team to build on that foundation and deliver lasting value for the members, clients and shareholders we serve.”
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms and partners —transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/642c837e-ba21-4636-9b33-efb5724b5398
Teladoc Health Appoints Michael Grasher as Chief Financial Officer Mr. Grasher is an accomplished financial executive with more than three decades of experience across...
Teladoc Health said on Monday it appointed Michael Grasher as its chief financial officer, bringing in an industry veteran to help the virtual healthcare company navigate rising demand for its insurance-covered business.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, Teladoc reported its financial results for the second quarter of 2026 and updated its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, compared to prior guidance in the range of $2.48 billion to $2.58 billion. Teladoc cited “uncertainties inherent in cash pay and ongoing business model transition”. The Company also identified various pressures facing its BetterHelp platform, including faster insurance preference, accelerated cash pay decline, and network capacity lagging demand.
On this news, Teladoc’s stock price fell $2.60 per share, or 38.32%, to close at $6.58 per share on July 30, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, Teladoc reported its financial results for the second quarter of 2026 and updated its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, compared to prior guidance in the range of $2.48 billion to $2.58 billion. Teladoc cited "uncertainties inherent in cash pay and ongoing business model transition". The Company also identified various pressures facing its BetterHelp platform, including faster insurance preference, accelerated cash pay decline, and network capacity lagging demand.
On this news, Teladoc's stock price fell $2.60 per share, or 38.32%, to close at $6.58 per share on July 30, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
A month has gone by since the last earnings report for Teladoc (TDOC - Free Report) . Shares have lost about 3.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Teladoc due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
Teladoc Health reported a second-quarter 2026 adjusted loss of 21 cents per share, which beat the Zacks Consensus Estimate of a loss of 24 cents. However, the bottom line deteriorated from a loss of 19 cents per share in the year-ago quarter.
Operating revenues declined 4% year over year to $606.9 million and missed the Zacks Consensus Estimate by 1.3%.
The quarterly results were supported by strength in the Integrated Care segment, higher international revenues and lower operating expenses, which were partially offset by weakness in the BetterHelp segment, particularly pressure on cash pay revenues, and declining access fees revenues.
Q2 Operational Update of Teladoc HealthRevenues from access fees totaled $474.2 million, down 9% year over year. The figure missed the Zacks Consensus Estimate and our estimate of $499.5 million. Other revenues increased 23% year over year to $132.7 million. The metric beat the Zacks Consensus Estimate and our estimate of $113 million.
On a geographical basis, Teladoc Health generated $487.4 million in revenues from the United States, down 6% year over year. The metric lagged the Zacks Consensus Estimate of $498.3 million. International revenues of $119.6 million advanced 7% year over year and surpassed the consensus mark of $114.2 million.
Adjusted EBITDA declined 5% year over year to $65.7 million and beat our estimate of $56.2 million. Total costs and expenses decreased 6.2% year over year to $644 million and came below our estimate of $661 million. The year-over-year decline was primarily due to lower technology and development, advertising and marketing, and general and administrative expenses.
TDOC Q2 Segmental UpdateThe Integrated Care segment’s revenues increased 1% year over year to $394.3 million in the reported quarter. The figure beat the Zacks Consensus Estimate of $392.2 million and our estimate of $392 million. Adjusted EBITDA increased 14% year over year to $65.2 million and surpassed the Zacks Consensus Estimate of $59.3 million. The adjusted EBITDA margin expanded 180 basis points (bps) year over year to 16.5%.
The BetterHelp segment generated revenues of $212.6 million, down 12% year over year. The metric missed the Zacks Consensus Estimate of $221.8 million. Adjusted EBITDA declined 96% year over year to $0.47 million. The figure missed the consensus mark of $1.8 million. The adjusted EBITDA margin of 0.2% contracted 470 bps year over year.
Visits & Memberships of Teladoc HealthTotal visits to Teladoc Health were 4.1 million in the second quarter, down 2% year over year. The metric beat the Zacks Consensus Estimate by 1.2%
U.S. Integrated Care members totaled 100.3 million, down 2% year over year. However, the figure beat the consensus mark by 0.7%.
TDOC’s Q2 Financial UpdateTeladoc Health exited the second quarter of 2026 with cash and cash equivalents of $774.3 million, down from $781.1 million as of 2025-end.
Total assets decreased to $2.76 billion from $2.86 billion at the end of 2025.
Debt totaled $996.7 million, up from $994.9 million as of 2025-end.
Total stockholders’ equity declined to $1.3 billion from $1.4 billion as of Dec. 31, 2025.
In the second quarter of 2026, TDOC generated net cash from operations of $64.7 million, down 29.3% year over year. Free cash flow was $35.7 million, down 41.6% year over year.
Teladoc Health’s Q3 2026 OutlookRevenues in the Integrated Care segment are forecasted to witness year-over-year growth of 0.0-3.0%. The unit’s adjusted EBITDA margin is anticipated to be in the band of 15.7-17.2%. U.S. Integrated Care members are expected to be between 99.0-100.5 million
Revenues in the BetterHelp segment are estimated to register a 12.3-24.2% year-over-year decline. The segment’s adjusted EBITDA margin is anticipated to be in the band of 0.5-2.5%.
Total revenues are expected to be between $569 million and $609 million. Adjusted EBITDA is anticipated to be between $62 million and $74 million. Net loss per share is estimated to be between 20 cents and 30 cents.
Teladoc Health’s 2026 outlookRevenues in the Integrated Care segment are expected to grow 0.8-2.4% year over year compared with the prior guidance of 0.8-3.5%. U.S. Integrated Care members are projected to be between 98.5 million and 100.5 million, up from the earlier projection of 97-100 million. The segment's adjusted EBITDA margin is expected to be between 15.6% and 16.4% compared with the previous guidance of 15.1-16.1%.
Revenues in the BetterHelp segment are expected to decline 12.7-19.0% year over year compared with the earlier guidance of 1.0-6.5%. The segment's adjusted EBITDA margin is expected to be between 3.0% and 4.6%, unchanged from the prior guidance.
The company expects 2026 revenues to be in the range of $2.362-$2.447 billion, down from the previous guidance of $2.481-$2.576 billion. Adjusted EBITDA is projected to be between $271 million and $303 million compared with the earlier outlook of $267-$306 million. Net loss per share is expected to be between 75 cents and $1.00 versus the previous guidance of 75 cents-$1.05.
Free cash flow guidance remains unchanged at $130-$170 million.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -27.35% due to these changes.
VGM ScoresCurrently, Teladoc has a average Growth Score of C, however its Momentum Score is doing a bit better with a B. Following the exact same course, the stock has a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Teladoc has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerTeladoc belongs to the Zacks Medical Services industry. Another stock from the same industry, Medpace (MEDP - Free Report) , has gained 5.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Medpace reported revenues of $707.33 million in the last reported quarter, representing a year-over-year change of +17.2%. EPS of $4.25 for the same period compares with $3.10 a year ago.
Medpace is expected to post earnings of $4.39 per share for the current quarter, representing a year-over-year change of +13.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Medpace. Also, the stock has a VGM Score of C.
Key Takeaways TDOC's BetterHelp sees insurance demand surge as users shift from paying out of pocket.More than 8,000 mental health professionals are credentialed as Teladoc expands insurance capacity.Insurance revenues hit $22 million in Q2 2026, up about $9 million sequentially. Teladoc Health, Inc.’s (TDOC - Free Report) lower revenue outlook may look alarming at first glance, but the underlying BetterHelp story is different. Demand has not disappeared; it has just shifted. Around 70% of prospective users prefer insurance over paying out of pocket, reaching as much as 80% in certain markets, creating a sharp increase in demand for covered therapy.
The problem is provider capacity. Insurance requires therapists to be credentialed with specific payers and available in the right states, making supply harder to scale than cash pay. As demand shifted faster than capacity, cash-pay revenues declined more rapidly than expected, while insurance revenues were not yet sufficient to offset the decline.
The company is prioritizing therapist recruitment, retention and credentialing, with more than 8,000 mental health professionals already credentialed. Company-wide advertising and marketing spending fell 12.2% in the first half of 2026 as resources shifted toward insurance. Meanwhile, insurance revenues reached $22 million in the second quarter of 2026, up roughly $9 million sequentially, while insurance users grew more than 70% sequentially.
The next phase depends on how quickly Teladoc can convert this demand into completed therapy visits. The company expects the insurance business to reach an annualized revenue run rate of nearly $140 million by the end of the fourth quarter of 2026, with further growth anticipated in 2027. If capacity catches up with demand, BetterHelp could reduce its reliance on costly customer acquisition, while the insurance model could support more durable economics and make customer lifetime value more reflective of patient need.
How Are Competitors Faring?Some of Teladoc’s key peers across digital health include Hims & Hers Health, Inc. (HIMS - Free Report) and American Well Corporation (AMWL - Free Report)
Hims & Hers Health operates a consumer-centric digital healthcare model, with mental health offered alongside a broader range of cash-pay wellness and personalized treatments. By relying heavily on direct-to-consumer engagement and marketing, HIMS provides a useful benchmark for customer acquisition efficiency, digital consumer access and the economics of cash-pay healthcare.
American Well takes a more enterprise-oriented approach, partnering with employers, and health systems to deliver digital care infrastructure. With exposure to behavioral health and insurance-covered care, AMWL provides a useful reference point for payer integration, clinical network scaling, and the economics of in-network virtual care.
Teladoc Health’s Price Performance, Valuation & EstimatesShares of TDOC have lost 16.7% over the past year compared to the industry’s 13.3% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, TDOC trades at a forward price-to-sales ratio of 0.48X, down from the industry average of 0.54X. TDOC carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TDOC’s 2026 loss is pegged at 89 cents per share,implying a 21.9% increase from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, Teladoc reported its financial results for the second quarter of 2026 and updated its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, compared to prior guidance in the range of $2.48 billion to $2.58 billion. Teladoc cited "uncertainties inherent in cash pay and ongoing business model transition". The Company also identified various pressures facing its BetterHelp platform, including faster insurance preference, accelerated cash pay decline, and network capacity lagging demand.
On this news, Teladoc's stock price fell $2.60 per share, or 38.32%, to close at $6.58 per share on July 30, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, Teladoc reported its financial results for the second quarter of 2026 and updated its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, compared to prior guidance in the range of $2.48 billion to $2.58 billion. Teladoc cited “uncertainties inherent in cash pay and ongoing business model transition”. The Company also identified various pressures facing its BetterHelp platform, including faster insurance preference, accelerated cash pay decline, and network capacity lagging demand.
On this news, Teladoc’s stock price fell $2.60 per share, or 38.32%, to close at $6.58 per share on July 30, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights.
We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Teladoc Health, Inc. (NYSE: TDOC) breached their fiduciary duties to shareholders.
If you currently own Teladoc stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
California State Teachers Retirement System raised its stake in shares of Teladoc Health, Inc. (NYSE:TDOC – Free Report) by 61.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 274,441 shares of the health services provider’s stock after buying an additional 104,160 shares during the quarter. California State Teachers Retirement System owned about 0.15% of Teladoc Health worth $1,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently modified their holdings of TDOC. PNC Financial Services Group Inc. increased its stake in Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after acquiring an additional 2,810 shares during the last quarter. IFP Advisors Inc boosted its position in shares of Teladoc Health by 412.1% during the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Teladoc Health during the 4th quarter valued at approximately $45,000. Van ECK Associates Corp grew its holdings in shares of Teladoc Health by 101.4% in the fourth quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock valued at $64,000 after purchasing an additional 4,607 shares in the last quarter. Finally, KBC Group NV grew its holdings in shares of Teladoc Health by 88.3% in the fourth quarter. KBC Group NV now owns 9,632 shares of the health services provider’s stock valued at $67,000 after purchasing an additional 4,516 shares in the last quarter. Institutional investors own 76.82% of the company’s stock.
Teladoc Health Trading Up 3.4% TDOC stock opened at $6.94 on Friday. Teladoc Health, Inc. has a 12 month low of $4.40 and a 12 month high of $9.89. The company has a 50-day moving average price of $8.15 and a 200 day moving average price of $6.57. The stock has a market cap of $1.26 billion, a PE ratio of -7.01 and a beta of 2.12.
Teladoc Health (NYSE:TDOC – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. The company had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Sell-side analysts forecast that Teladoc Health, Inc. will post -0.88 EPS for the current year.
Analyst Upgrades and Downgrades TDOC has been the topic of a number of recent research reports. Bank of America upped their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Citigroup decreased their target price on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research report on Monday, August 3rd. Finally, Canaccord Genuity Group dropped their price target on Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.54.
Check Out Our Latest Analysis on TDOC
Insiders Place Their Bets In related news, insider Carlos Nueno sold 6,196 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the completion of the transaction, the insider owned 57,671 shares in the company, valued at $440,029.73. The trade was a 9.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of Teladoc Health stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the sale, the insider owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 39,195 shares of company stock valued at $299,058. Corporate insiders own 0.70% of the company’s stock.
Teladoc Health Company Profile (Free Report)
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
Further Reading Five stocks we like better than Teladoc Health Asian Market Circuit Breakers Hit Stocks, Not AI Demand Riot Platforms Re-Wires the Ledger for a $9B AI Power Play Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy? Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFirst Nebraska Trust Co Acquires New Position in Amazon.com, Inc. $AMZN
NEXT HEADLINE »OUTFRONT Media Inc. $OUT Shares Sold by Empowered Funds LLC
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, Teladoc reported its financial results for the second quarter of 2026 and updated its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, compared to prior guidance in the range of $2.48 billion to $2.58 billion. Teladoc cited "uncertainties inherent in cash pay and ongoing business model transition". The Company also identified various pressures facing its BetterHelp platform, including faster insurance preference, accelerated cash pay decline, and network capacity lagging demand.
On this news, Teladoc's stock price fell $2.60 per share, or 38.32%, to close at $6.58 per share on July 30, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Teladoc Health shares fell more than 28% after the Company reported Q2 2026 revenue of $606.9 million and cut its full-year 2026 revenue guidance. Levi & Korsinsky investigates.
, /PRNewswire/ -- Teladoc Health (NYSE: TDOC) shares dropped more than 28% after the Company reported second quarter 2026 consolidated revenue of $606.9 million -- below the consensus range of $615 million to $628 million -- and lowered its full-year 2026 revenue outlook to $2.36 billion to $2.45 billion. If you suffered a loss on your Teladoc Health investment, you are encouraged to click here to submit your information . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
On February 25, 2026, Teledoc issued revenue guidance of $2.47 billion to $2.59 billion, and further specifically projected a revenue decline for the BetterHelp division of 7% to 0.5%. During the Company's Q1 report on April 29, 2026, both of these ranges were narrowed, with revenue guidance updated to a range of approximately $2.48 billion to $2.57 billion and BetterHelp projected to decline 6.5% to 1% for the full year.
On the Company's July 29, 2025 earnings call, Teladoc CEO, Charles Divita, noted that the "BetterHelp revenue growth outlook provided with our first quarter results assumed we would achieve the dual goals of scaling insurance, while at the same time stabiliizing and growing overall BetterHelp segment revenues." He further disclosed that the "decline in cash pay users … accelerated beyond the decline incorporated in our prior outlook" and insurance capacity "did not expand at the same pace as the increase in demand."
Shareholders who lost money on TDOC are encouraged to have their losses evaluated at no cost before the investigation concludes.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the TDOC Investigation
Q: What is the TDOC securities investigation about? A: A securities investigation is pending concerning Teladoc Health (NYSE: TDOC) regarding potentially materially false or misleading statements about the Company's forward revenue outlook. Shares were falling nearly 30% following Teladoc's full-year 2026 revenue guidance cut.
Q: Who is eligible to participate in the TDOC investigation? A: Investors who purchased TDOC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did TDOC stock drop? A: Shares fell nearly 30% after the Company reported Q2 2026 consolidated revenue of $606.9 million, below consensus expectations, and cut its full-year guidance. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: What do TDOC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my TDOC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TDOC and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Teladoc Health Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TELADOC HEALTH INC. (TDOC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On July 29, 2025, the Company reported second quarter earnings, including that the Company’s full year revenue guidance was reduced a ceiling below its prior floor, with Teladoc now only projecting $2.36 billion to $2.45 billion revenue for the full year. BetterHelp's segment performance was reduced more drastically, with the Company now projecting a loss of 19% to 12.7% for the full year.
In the accompanying earnings call held the same day, management explained "[a]s we moved through the second half of May and into June, the increasing speed of consumer movement towards insurance, provider capacity and network constraints against this increased demand, and a more accelerated decline in cash pay users and other factors became more pronounced and persistent than the assumptions underlying our prior outlook. These developments led us to reassess our plans and priorities and accordingly revise our BetterHelp revenue outlook."
On this news, shares of Teladoc fell $2.60 or 28.3% to close at $6.58 per share on July 30, 2026, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Teladoc Health Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Teladoc Health Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON TELADOC HEALTH INC. (TDOC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 29, 2025, the Company reported second quarter earnings, including that the Company’s full year revenue guidance was reduced a ceiling below its prior floor, with Teladoc now only projecting $2.36 billion to $2.45 billion revenue for the full year. BetterHelp's segment performance was reduced more drastically, with the Company now projecting a loss of 19% to 12.7% for the full year.
In the accompanying earnings call held the same day, management explained "[a]s we moved through the second half of May and into June, the increasing speed of consumer movement towards insurance, provider capacity and network constraints against this increased demand, and a more accelerated decline in cash pay users and other factors became more pronounced and persistent than the assumptions underlying our prior outlook. These developments led us to reassess our plans and priorities and accordingly revise our BetterHelp revenue outlook."
On this news, shares of Teladoc fell $2.60 or 28.3% to close at $6.58 per share on July 30, 2026, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Teladoc Health Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. ("Teladoc" or the "Company") (NYSE: TDOC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, Teladoc reported its financial results for the second quarter of 2026 and updated its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, compared to prior guidance in the range of $2.48 billion to $2.58 billion. Teladoc cited "uncertainties inherent in cash pay and ongoing business model transition". The Company also identified various pressures facing its BetterHelp platform, including faster insurance preference, accelerated cash pay decline, and network capacity lagging demand.
On this news, Teladoc's stock price fell $2.60 per share, or 38.32%, to close at $6.58 per share on July 30, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Teladoc Health Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TELADOC HEALTH INC. (TDOC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On July 29, 2025, the Company reported second quarter earnings, inc.
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- A revenue shortfall of up to $21 million against Wall Street estimates wiped out roughly a quarter of Teladoc Health's (NYSE: TDOC) market value, with shares dropping around 29% intraday after the Company posted Q2 2026 consolidated revenue of $606.9 million. If you lost money on TDOC shares, you are encouraged to click here to submit your losses for review. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Consensus estimates going into the print ranged from $615 million to $628 million. Reported revenue came in at $606.9 million -- down approximately 4% year-over-year and below the low end of the analyst range, alongside BetterHelp segment revenue of only $212.6 million, down 12%. year-over-year. GAAP EPS of -$0.21 beat the -$0.25 consensus, but the top-line miss drove the selloff.
Alongside the miss, Teladoc reduced its full-year 2026 revenue outlook to $2.36 billion to $2.45 billion and slashed BetterHelp segment revenue growth expectations to decline 19% to 12.7%.
Shareholders who purchased TDOC and suffered a loss on the earnings miss may request a no-cost review of their recovery options, or call (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the TDOC Investigation
Q: How much did TDOC stock drop? A: Shares fell nearly 30% after the Company reported Q2 2026 consolidated revenue of $606.9 million, below consensus expectations, and cut its full-year guidance. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: What is the TDOC investigation about? A: A securities investigation is pending concerning Teladoc Health (NYSE: TDOC) regarding potentially materially false or misleading statements about the Company's forward revenue outlook. Shares were falling nearly 30% following Teladoc’s full-year 2026 revenue guidance cut.
Q: Who is eligible to participate in the TDOC investigation? A: Investors who purchased TDOC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do TDOC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my TDOC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TDOC and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations are generally handled on a contingency basis -- no upfront fees, no retainer, and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
NEW YORK--(BUSINESS WIRE)--Five months after guiding full-year 2026 consolidated revenue to a range of $2.47 billion to $2.59 billion, Teladoc Health (NYSE: TDOC) reduced that outlook to $2.36 billion to $2.45 billion, and shares fell nearly 30%. If you lost money holding Teladoc Health shares, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.On the February 25, 2026 fourth qua.
Five months after guiding full-year 2026 consolidated revenue to a range of $2.47 billion to $2.59 billion, Teladoc Health (NYSE: TDOC) reduced that outlook to
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare is the former president and chief operating officer of Verisk Analytics, a strategic data analytics and technology partner to the global insurance industry. He will serve on the board's Audit & Compensation committees.
Teladoc Health issued full-year 2026 revenue guidance of $2.47 billion to $2.59 billion in February 2026, then cut the low end by roughly $110 million months later -- and the stock fell nearly 30%. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of TDOC shareholders.
, /PRNewswire/ -- A guidance reduction of $108 million at the bottom end following last quarter's slight uplift wiped nearly 30% of Teladoc Health (NYSE: TDOC) shareholder value after the Company lowered its full-year 2026 revenue outlook to $2.36 billion to $2.45 billion. Shareholders who lost money on TDOC are encouraged to submit their loss information here . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.
On the February 25, 2026 earnings call, Chief Executive Officer Charles Divita told investors: "We expect full-year consolidated revenue to be in the range of $2.47 billion to $2.59 billion, approximately leveled with 2025 at the midpoint." The revised range announced with Q2 2026 results sits entirely below the previous range.
Investors who purchased Teladoc Health shares and suffered a loss are encouraged to click here to learn more about the investigation or call (888) SueWallSt.
WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the TDOC Investigation
Q: What is the TDOC investigation about? A: A securities investigation is pending concerning Teladoc Health (NYSE: TDOC) regarding potentially materially false or misleading statements about the Company's forward revenue outlook. Shares were falling nearly 30% following Teladoc's full-year 2026 revenue guidance cut.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Teladoc Health made materially false or misleading statements regarding its reported revenue figures and how those figures were characterized relative to guidance on earnings calls.
Q: Who is eligible to participate in the TDOC investigation? A: Investors who purchased TDOC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do TDOC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt, a brand of Levi & Korsinsky LLP, for a no-cost, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my TDOC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TDOC and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected] \
Tel: (888) SueWallSt\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company value investors might notice is Teladoc Health (TDOC - Free Report) . TDOC is currently holding a Zacks Rank #2 (Buy) and a Value grade of A.
Investors should also recognize that TDOC has a P/B ratio of 0.99. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 2.09. TDOC's P/B has been as high as 1.65 and as low as 0.80, with a median of 1.01, over the past year.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. TDOC has a P/S ratio of 0.49. This compares to its industry's average P/S of 1.42.
Finally, our model also underscores that TDOC has a P/CF ratio of 6.35. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. TDOC's P/CF compares to its industry's average P/CF of 12.51. Within the past 12 months, TDOC's P/CF has been as high as 14.43 and as low as 5.41, with a median of 7.42.
These are only a few of the key metrics included in Teladoc Health's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, TDOC looks like an impressive value stock at the moment.
Teladoc Health projected its BetterHelp division to decline 7% to 0.5%. Following a quarter that featured a 12% annual decline, the Company is now telling investors to expect up to a 19% full-year revenue growth decline.
, /PRNewswire/ -- Teladoc Health (NYSE: TDOC) shareholders watched more than 28% of their position disappear in a single session after the Company reported Q2 2026 consolidated revenue of $606.9 million. If you lost money on TDOC, get your losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
On February 25, 2026, Teledoc issued revenue guidance of $2.47 billion to $2.59 billion, and further specifically projected a revenue decline for the BetterHelp division of 7% to 0.5%. During the Company's Q1 report on April 29, 2026, both of these ranges were narrowed, with revenue guidance updated to a range of approximately $2.48 billion to $2.57 billion and BetterHelp projected to decline 6.5% to 1% for the full year.
On the Company's July 29, 2025 earnings call, CEO Divita admitted "that assumptions supporting our prior full year Better Help segment revenue expectations are no longer representative of the business outlook." Revenue guidance was reduced a ceiling below its prior floor, with Teladoc now only projecting $2.36 billion to $2.45 billion. BetterHelp's segment performance was reduced more drastically, with the Company now projecting a loss of 19% - 12.7%.
Shareholders who purchased TDOC and suffered losses are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the TDOC Investigation
Q: How much did TDOC stock drop? A: Shares fell nearly 30% after the Company reported Q2 2026 consolidated revenue of $606.9 million, below consensus expectations, and cut its full-year guidance. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Teladoc Health made materially false or misleading statements regarding its reported revenue figures and how those figures were characterized relative to guidance on earnings calls.
Q: Who is eligible to participate in the TDOC investigation? A: Investors who purchased TDOC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do TDOC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my TDOC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TDOC and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected] \
Tel: (212) 363-7500\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Key Takeaways TDOC posted a lower-than-expected adjusted loss despite a 4% year-over-year revenue decline.Teladoc Health saw Integrated Care revenue and margin growth, while BetterHelp revenues and EBITDA dropped.TDOC cut its 2026 revenue outlook but lifted its Integrated Care membership forecast and margin guidance. Teladoc Health, Inc. (TDOC - Free Report) reported a second-quarter 2026 adjusted loss of 21 cents per share, which beat the Zacks Consensus Estimate of a loss of 24 cents. However, the bottom line deteriorated from a loss of 19 cents per share in the year-ago quarter.
Operating revenues declined 4% year over year to $606.9 million and missed the Zacks Consensus Estimate by 1.3%.
The quarterly results were supported by strength in the Integrated Care segment, higher international revenues and lower operating expenses, which were partially offset by weakness in the BetterHelp segment, particularly pressure on cash pay revenues, and declining access fees revenues.
Teladoc Health, Inc. Price, Consensus and EPS SurpriseQ2 Operational Update of Teladoc HealthRevenues from access fees totaled $474.2 million, down 9% year over year. The figure missed the Zacks Consensus Estimate and our estimate of $499.5 million. Other revenues increased 23% year over year to $132.7 million. The metric beat the Zacks Consensus Estimate and our estimate of $113 million.
On a geographical basis, Teladoc Health generated $487.4 million in revenues from the United States, down 6% year over year. The metric lagged the Zacks Consensus Estimate of $498.3 million. International revenues of $119.6 million advanced 7% year over year and surpassed the consensus mark of $114.2 million.
Adjusted EBITDA declined 5% year over year to $65.7 million and beat our estimate of $56.2 million. Total costs and expenses decreased 6.2% year over year to $644 million and came below our estimate of $661 million. The year-over-year decline was primarily due to lower technology and development, advertising and marketing, and general and administrative expenses.
TDOC Q2 Segmental UpdateThe Integrated Care segment’s revenues increased 1% year over year to $394.3 million in the reported quarter. The figure beat the Zacks Consensus Estimate of $392.2 million and our estimate of $392 million. Adjusted EBITDA increased 14% year over year to $65.2 million and surpassed the Zacks Consensus Estimate of $59.3 million. The adjusted EBITDA margin expanded 180 basis points (bps) year over year to 16.5%.
The BetterHelp segment generated revenues of $212.6 million, down 12% year over year. The metric missed the Zacks Consensus Estimate of $221.8 million. Adjusted EBITDA declined 96% year over year to $0.47 million. The figure missed the consensus mark of $1.8 million. The adjusted EBITDA margin of 0.2% contracted 470 bps year over year.
Visits & Memberships of Teladoc HealthTotal visits to Teladoc Health were 4.1 million in the second quarter, down 2% year over year. The metric beat the Zacks Consensus Estimate by 1.2%
U.S. Integrated Care members totaled 100.3 million, down 2% year over year. However, the figure beat the consensus mark by 0.7%.
TDOC’s Q2 Financial UpdateTeladoc Health exited the second quarter of 2026 with cash and cash equivalents of $774.3 million, down from $781.1 million as of 2025-end.
Total assets decreased to $2.76 billion from $2.86 billion at the end of 2025.
Debt totaled $996.7 million, up from $994.9 million as of 2025-end.
Total stockholders’ equity declined to $1.3 billion from $1.4 billion as of Dec. 31, 2025.
In the second quarter of 2026, TDOC generated net cash from operations of $64.7 million, down 29.3% year over year. Free cash flow was $35.7 million, down 41.6% year over year.
Teladoc Health’s Q3 2026 OutlookRevenues in the Integrated Care segment are forecasted to witness year-over-year growth of 0.0-3.0%. The unit’s adjusted EBITDA margin is anticipated to be in the band of 15.7-17.2%. U.S. Integrated Care members are expected to be between 99.0-100.5 million
Revenues in the BetterHelp segment are estimated to register a 12.3-24.2% year-over-year decline. The segment’s adjusted EBITDA margin is anticipated to be in the band of 0.5-2.5%.
Total revenues are expected to be between $569 million and $609 million. Adjusted EBITDA is anticipated to be between $62 million and $74 million. Net loss per share is estimated to be between 20 cents and 30 cents.
Teladoc Health’s 2026 outlookRevenues in the Integrated Care segment are expected to grow 0.8-2.4% year over year compared with the prior guidance of 0.8-3.5%. U.S. Integrated Care members are projected to be between 98.5 million and 100.5 million, up from the earlier projection of 97-100 million. The segment's adjusted EBITDA margin is expected to be between 15.6% and 16.4% compared with the previous guidance of 15.1-16.1%.
Revenues in the BetterHelp segment are expected to decline 12.7-19.0% year over year compared with the earlier guidance of 1.0-6.5%. The segment's adjusted EBITDA margin is expected to be between 3.0% and 4.6%, unchanged from the prior guidance.
The company expects 2026 revenues to be in the range of $2.362-$2.447 billion, down from the previous guidance of $2.481-$2.576 billion. Adjusted EBITDA is projected to be between $271 million and $303 million compared with the earlier outlook of $267-$306 million. Net loss per share is expected to be between 75 cents and $1.00 versus the previous guidance of 75 cents-$1.05.
Free cash flow guidance remains unchanged at $130-$170 million.
TDOC’s Zacks RankTeladoc Health currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
How Did Other Medical Companies Perform?Here are some stocks from the broader Medical space that have also reported their quarterly results: Acadia Healthcare Company, Inc. (ACHC - Free Report) , Elevance Health, Inc. (ELV - Free Report) and UnitedHealth Group Incorporated (UNH - Free Report) . Here's how they have performed:
Acadia Healthcare reported adjusted second-quarter earnings of 38 cents per share, which beat the Zacks Consensus Estimate by 15.2%. However, the bottom line declined 54% year over year. Acadia Healthcare’s top line declined 0.4% year over year to $865.8 million and surpassed the Zacks Consensus Estimate by 2.5%. The quarterly results reflected strong patient demand, as admissions increased and same-facility patient days improved. Residential Treatment Facilities also delivered double-digit revenue growth. However, lower revenue per patient day, a shorter average length of stay and higher operating expenses weighed on profitability.
Elevance Health reported second-quarter 2026 adjusted earnings per share of $7.45, which surpassed the Zacks Consensus Estimate by 20.6%. However, the bottom line declined 15.7% year over year. Operating revenues advanced 0.8% year over year to $49.8 billion. The top line beat the consensus mark by 2.9%. Elevance Health’s quarterly results were primarily driven by higher premium yields in the Health Benefits segment and increased CarelonRx product revenues. The gains were partly offset by a decline in overall medical membership and higher operating expenses.
UnitedHealth Group reported second-quarter 2026 adjusted earnings per share of $6.38, which beat the Zacks Consensus Estimate of $4.94. The bottom line rose 56.4% year over year. Revenues rose 0.4% year over year to $112 billion. The top line beat the consensus mark by 1.7%. UnitedHealth Group’s strong quarterly results were aided by growth in commercial fee-based membership and the strength in Optum Insight. Medical cost management, pricing discipline and benefit design changes also contributed to the upside. However, weaker performance at Optum Health and Optum Rx, along with declining risk-based membership, partially offset these gains.
3 Non-Pharma Firms That Could Benefit From the GLP-1 TrendTeladoc Health NYSE: TDOC reported second-quarter results within its consolidated guidance range, supported by stronger-than-expected profitability in its Integrated Care segment, while lower cash-pay revenue at BetterHelp prompted the company to reduce its full-year revenue outlook.
Consolidated revenue totaled $607 million for the quarter, while adjusted EBITDA was $66 million, representing a 10.8% margin. Teladoc reported a net loss of $0.21 per share and generated $36 million in free cash flow. The company ended the quarter with $774 million in cash and cash equivalents, with net debt equal to 0.8 times trailing adjusted EBITDA.
Get Teladoc Health alerts:
Integrated Care Posts Revenue and Margin Gains Peloton Stock Is Rallying, But Can It Deliver Another 70% Upside?Integrated Care revenue rose 0.7% year over year to $394 million, landing in the upper half of Teladoc’s guidance range. The segment’s adjusted EBITDA increased 13.6% from a year earlier to $65 million, producing a 16.5% margin that was above the company’s guidance range.
Chief Executive Officer Chuck Divita said international revenue again increased by double digits, aided by a 30% increase in hybrid-care-model revenue. Higher chronic-care enrollment and visit revenue also contributed, more than offsetting lower subscription revenue. Acquisitions accounted for approximately 60 basis points of year-over-year growth.
2 Telehealth Stocks That Could Gain from Trump’s New FDA PickTeladoc ended the quarter with 100.3 million U.S. Integrated Care members, slightly above its forecast range. Chronic-care enrollment reached 1.27 million, up 6% sequentially and 14% year over year, driven largely by clients adopting multi-condition bundles.
The company recently introduced Teladoc One, a connected-care model that combines its clinical and technology capabilities around an individual’s healthcare needs. The offering will initially target people with cardiometabolic health conditions and is expected to become broadly available in January 2027. Divita said Teladoc One will use the company’s Pulse intelligence engine, which applies multidimensional data and artificial intelligence models to support clinical insights, interventions and engagement.
For 2026, Teladoc expects Integrated Care revenue growth of 0.8% to 2.4% and an adjusted EBITDA margin of 15.6% to 16.4%. The company said its revenue outlook reflects a client-requested deferral of a planned contract implementation and a lower expected foreign-exchange benefit. It continues to anticipate high-single-digit organic constant-currency international revenue growth.
BetterHelp Transition Pressures Cash-Pay Revenue BetterHelp revenue declined 11.6% year over year to $213 million and fell 2.6% sequentially. Insurance revenue was $22 million, near the high end of Teladoc’s expected range and about $9 million higher sequentially. However, the gain was offset by a sharper-than-expected drop in cash-pay revenue.
Average BetterHelp paying users fell 11% year over year to 346,000 and declined 4% from the first quarter. Insurance users, meanwhile, increased more than 70% sequentially. BetterHelp generated adjusted EBITDA of $0.5 million, or a 0.2% margin, as lower cash-pay revenue and investments in the accelerated insurance rollout outweighed a 17% reduction in advertising and marketing expense from a year earlier.
Divita said demand for insurance coverage accelerated during the latter half of May and into June. About 70% of potential users indicated a preference for insurance, rising to as much as 80% in certain markets, according to the company. The shift reduced cash-pay conversion and increased demand beyond available provider capacity in some states and payer networks.
While Teladoc has credentialed more than 8,000 mental-health professionals for BetterHelp’s insurance network and contracted for more than $150 million of in-network lives, Divita said capacity depends on provider availability by state, payer, clinical need and appointment timing. The company completed more than 20,000 insurance-covered sessions in the most recent week cited, representing an annualized revenue run rate of more than $110 million.
Teladoc accelerated BetterHelp’s national insurance expansion, launching its remaining states during the quarter and establishing a baseline footprint across all 50 states and Washington, D.C. The company plans to focus resources on provider recruitment, onboarding, retention, scheduling efficiency and insurance-platform improvements. It also intends to align advertising more closely with available insurance-provider capacity and shift from state-level to more national insurance marketing strategies.
The company is reducing near-term emphasis on international BetterHelp markets, including related advertising and resource allocation, as it prioritizes the U.S. insurance opportunity. Divita said the move is a near-term prioritization rather than a departure from international markets, where Teladoc still sees long-term opportunity.
Full-Year Revenue Outlook Reduced Teladoc lowered its 2026 consolidated revenue outlook to $2.36 billion to $2.45 billion, a 5% reduction at the midpoint from its prior range, primarily because of the revised BetterHelp cash-pay outlook. The company maintained its free-cash-flow outlook of $130 million to $170 million.
Adjusted EBITDA guidance was raised slightly at the midpoint to a range of $271 million to $303 million, which would represent about 85 basis points of margin expansion from 2025. Teladoc now expects a net loss of $1.00 to $0.75 per share for the year and projects stock-based compensation expense below $50 million, down more than 35% from 2025.
BetterHelp’s 2026 revenue is now expected to decline 19.0% to 12.7% from 2025, with total segment revenue of $770 million to $830 million. Insurance revenue guidance for BetterHelp was reaffirmed at $90 million to $105 million for 2026. BetterHelp adjusted EBITDA margin guidance remains 3.0% to 4.6%. Third-quarter BetterHelp insurance revenue is projected at $25 million to $31 million. Divita said Teladoc expects insurance revenue to continue growing sequentially in the fourth quarter. At the midpoint of the company’s implied fourth-quarter range, BetterHelp’s insurance business would exit 2026 at an annualized revenue run rate approaching $140 million.
About Teladoc Health (NYSE:TDOC)Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Teladoc Health Right Now?Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Teladoc Health stock is taking a hit today. What’s behind TDOC decline? What Is Driving Teladoc’s Q2 Revenue Miss?Teladoc reported second-quarter revenue of $606.9 million (down 4% year-over-year) and a loss of 21 cents per share, while its third-quarter revenue guide of $569 million to $609 million landed below the Street view of $629.3 million. The company also guided to a third-quarter loss of 30 cents per share to a loss of 20 cents per share versus expectations for a loss of 18 cents per share.
Teladoc’s segment split is amplifying the guidance hit, with Integrated Care up 1% to $394.3 million while BetterHelp fell 12% to $212.6 million, alongside management’s comment that cash-pay pressure intensified in late May and early June.
CEO Chuck Divita also pointed to the U.S. launch of Teladoc One, the company’s new connected care model, as a longer-term product push even as near-term demand wobbles.
Critical Price Levels To Watch For TDOCThe premarket flush puts TDOC back below its shorter-term trend gauges, trading 20.6% below the 20-day SMA ($9.27) and 9.4% below the 50-day SMA ($8.12), which often turns recent "dip-buy" setups into "sell-the-rip" behavior. It’s still 5.9% above the 100-day SMA ($6.95) and 6.6% above the 200-day SMA ($6.91), so the longer-term base from late spring is being tested rather than fully broken.
MACD is the cleaner momentum lens here: it’s below its signal line with a negative histogram, which suggests upside pressure is fading unless buyers can quickly reclaim that baseline. In plain terms, MACD below the signal line typically means the recent uptrend is losing steam and rallies can stall sooner.
The moving-average structure is mixed: the 20-day SMA remains above the 50-day SMA (bullish), and the golden cross in June (50-day above 200-day) still argues the bigger trend improved earlier this summer. But with the recent swing high and 52-week high both set in July, this gap-down style move increases the odds that July becomes a more durable pivot zone overhead.
Key Resistance: $8.00 — a round-number area that also sits near the 50-day moving averages, where rebounds can run into supply Key Support: $7.00 — a nearby round-number level sitting close to the 200-day EMA ($7.30) and the longer-term moving-average cluster TDOC Stock Price Activity During Thursday PremarketTDOC Stock Price Activity: Teladoc Health shares were down 19.83% at $7.36 during premarket trading on Thursday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Teladoc shares fell more than 20% before the bell on Thursday, a day after the virtual healthcare provider trimmed its annual revenue forecast and flagged challenges at its mental health services unit BetterHelp.
